Physician profile
Stephen Infanger
NPI 1144675950
$6,063.36
in general payments reported to CMS, 2019-2025
25 companies · $1,379 in 2025
The $1,379 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $267 · 2023: $1,474 · 2024: $2,943 · 2025: $1,379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,797.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,796.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,240.07 | 2023-2025 | Repatha, Repatha |
| Abbott Laboratories | $1,006.96 | 2022-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, Amplatzer Amulet |
| Pfizer INC. | $613.54 | 2023-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $486.23 | 2023-2025 | Lifevest |
| Alnylam Pharmaceuticals INC. | $311.30 | 2024-2025 | Onpattro, Amvuttra |
| Medtronic, INC. | $272.38 | 2024-2025 | Corevalve Evolut R |
| Impulse Dynamics (USA) INC. | $256.01 | 2023 | Optimizer |
| Bayer Healthcare Pharmaceuticals INC. | $241.97 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $240.04 | 2023-2024 | Farxiga, Brilinta |
| Abiomed | $225.88 | 2023-2025 | Impella |
| Scpharmaceuticals INC. | $185.03 | 2024 | |
| Novo Nordisk INC | $183.14 | 2024-2025 | Ozempic |
| Cvrx, INC. | $159.64 | 2023-2024 | Barostim Neo System |
| Novartis Pharmaceuticals Corporation | $117.23 | 2023-2024 | |
| Kiniksa Pharmaceuticals International, Plc | $114.83 | 2024 | Arcalyst |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $109.21 | 2023-2024 | Verquvo, Winrevair |
| Boston Scientific Corporation | $76.77 | 2023-2024 | Watchman |
| Daiichi Sankyo INC. | $51.98 | 2022-2024 | Injectafer |
| Baxter Healthcare | $36.86 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Lilly USA, LLC | $30.80 | 2025 | Zepbound, Mounjaro |
| United Therapeutics Corporation | $28.16 | 2025 | Tyvaso |
| E.R. Squibb & Sons, L.L.C. | $23.24 | 2024 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.14 | 2024 | Jardiance |
| Inspire Medical Systems, INC. | $18.63 | 2023 | Inspire |
| Ge Healthcare | $14.32 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Infanger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.